Related Experiment Video
Updated: Apr 11, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cancer Immunotherapy: More Is (Much) Better
1Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. Yosef.yarden@weizmann.ac.il.
Abstract:
Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.
Insights
Researchers suggest replacing single antibodies with a six-antibody mixture targeting EGFR, HER2, and HER3 to improve cancer treatment response and overcome resistance. This approach enhances efficacy in patients with certain cancers.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Monoclonal antibodies targeting EGFR and HER2 are standard cancer therapies.
- Limited patient response and acquired resistance diminish the effectiveness of current antibody treatments.
Purpose of the Study:
- To present experimental evidence supporting a novel oligoclonal antibody mixture for cancer treatment.
- To investigate the synergistic effects of simultaneously engaging EGFR, HER2, and HER3.
Main Methods:
- Development and testing of an oligoclonal mixture comprising six synergistic antibodies.
- Evaluation of the antibody mixture's efficacy in preclinical cancer models.
Main Results:
- The six-antibody mixture demonstrated enhanced efficacy compared to individual antibodies.
- Simultaneous engagement of EGFR, HER2, and HER3 pathways showed synergistic anti-cancer activity.
Conclusions:
- An oligoclonal antibody mixture offers a promising alternative to current monoclonal antibodies for cancer therapy.
- This strategy may overcome resistance mechanisms and improve treatment outcomes for a broader patient population.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies